
NYSE:BDX
This summary was created by AI, based on 2 opinions in the last 12 months.
Becton Dickinson (BDX) has undergone significant structural changes, having recently spun off its life sciences business and merged it with Waters Corporation, thereby positioning itself as a pure-play medical technology company. This transformation aims to focus on higher-growth and higher-margin areas within the medical sector. Despite management's previous projections of $15 EPS, the new guidance suggests a more conservative estimate of $12.50 for 2026, while expectations for operating margins have risen from 21% to 25%. The stock is currently considered attractively priced at 14x earnings, but there are inherent risks associated with the ongoing changes. Furthermore, analysts have set a price target of $200.00, indicating a cautiously optimistic outlook. However, concerns remain regarding the macroeconomic environment, particularly given BDX's strong ties to hospital systems, which has caused some experts to adopt a wait-and-see approach before re-evaluating their investment stance.
(A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies.
It was a top pick for him in the past recently acquired CR Bald. A one stop shop for hospitals and clinics for all one time use medical devices (needles, etc.). Full service company from sales to programming to reordering, etc. now a gigantic company. Very good earnings. Very good guidance. They are going to benefit from tax reform. Big tail winds in healthcare. The biggest risk in healthcare is what Amazon is going to do. But not a lot of competition on the space. Just the US government spends 1.3 trillion dollars a year in health care.
Manufactures syringes and other medical devices. Just completed a big merger. The merger of 2 strong free cash flow growing companies has made them a powerhouse, and the stock has taken off after the announcement of the acquisition. Expectation is 10% free cash flow growth, and as a result, 10% dividend growth over time.